Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

About this update from Sunshine Biopharma Inc.

[{"type":"text","content":"FORT LAUDERDALE, FL / ACCESS Newswire / April 3, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced the closing of the previously announced registered direct offering with institutional investors of approximately $2.46 million of shares of Common Stock and pre-funded warrants at a price of $2.07 per share of Common Stock. The entire transaction was priced at the market under Nasdaq rules.","length":569,"tagName":"p"},{"type":"text","content":"The offering consisted of the sale of 1,188,404 shares of Common Stock (or Pre-Funded Warrants). The price per Common Share was $2.07 (or $2.06999 for each Pre-Funded Warrant, which is equal to the offering price per share of Common Stock sold in the offering minus an exercise price of $0.00001 per Pre-Funded Warrant). The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until exercised in full.","length":430,"tagName":"p"},{"type":"text","content":"The Company received aggregate gross proceeds from the offering of approximately $2.46 million. The transaction closed on April 3, 2025. The Company expects to use the net proceeds from the offering for general corporate purposes and working capital.","length":250,"tagName":"p"},{"type":"text","content":"Aegis Capital Corp. acted as exclusive placement agent for the offering. Sichenzia Ross Ference Carmel LLP acted as counsel to the Company. Kaufman & Canoles, P.C. acted as counsel to Aegis Capital Corp.","length":207,"tagName":"p"},{"type":"text","content":"The registered direct offering was made pursuant to an effective shelf registration statement on Form S-3 (No. 333-284142) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on January 15, 2025. A final prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC and is available on the SEC's website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicat...

More updates from Sunshine Biopharma Inc.